We are international
• meetings TEXT SIZE   

ASH Conference 2004 - December 3-7
Fri, Dec 03, 2004

San Diego, CA


The IMF and the ICHE will sponsor a Corporate Friday Symposium preceding the 46th American Society of Hematology (ASH) Annual Meeting in San Diego, California. The CME-certified symposium, "Controversies in Myeloma Management" will be held December 3, 2004, at 6:00 p.m. More....


Osteonecrosis of the Jaws in Myeloma:
Time Dependent Correlation with Aredia and Zometa Use

Speaker Brian G.M. Durie, M.D., Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA
Tuesday, December 7, 2004
8:30 a.m.

Amyloidosis and Waldenstrom's Macroglobulinemia

Chair: Morie A. Gertz, M.D., Mayo Clinic, Rochester, MN

Steven P. Treon, M.D., M.A., Ph.D., Dana-Farber Cancer Institute, Boston, MA
Waldenstrom's Macroglobulinemia: Biology and Management

Morie A. Gertz, M.D., Mayo Clinic, Rochester, MN
Amyloidosis: Establishing an Early Diagnosis and Risk Factor Assessment

Giampaolo Merlini, M.D., IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
Amyloidosis: Therapeutic Options 2004

Amyloidosis and Waldenstrom macroglobulinemia are rare immunoglobulin disorders in which new therapeutic innovations have developed in the past five years. A greater understanding of the biology of the disorders, as well as new methods of assessing the impact of intervention, have been developed. This session will update the attendee on the new diagnostic, prognostic, and therapeutic strategies to treat these rare monoclonal gammopathies.

Dr. Steven Treon will report on results from the first meeting of the Waldenstrom Macroglobulinemia Clinical Trials Collaborative Group held in April 2004, as well as the Third International Workshop on Waldenstrom Macroglobulinemia held in October 2004.

Dr. Morie Gertz will review a clinical algorithm to attain proper recognition and confirmation of the diagnosis of amyloid, as well as the new prognostic studies that have been developed in the disorder. The new monitoring techniques for patients on therapy will be reviewed.

Dr. Giampaolo Merlini will review the current status of conventional and high dose therapies for the management of amyloidosis, as well as some of the new phase II agents that have been introduced. An update from the International Amyloidosis Symposium, held April 2004, will also be provided. Today, virtually all patients with amyloidosis are candidates for therapy and clinical trials exist for the majority of patients.

Multiple Myeloma


Jean-Luc Harousseau, M.D., Hotel Dieu, Nantes, France


John Shaughnessy, Jr., Ph.D., University of Arkansas for Medical Sciences, Little Rock, AR
Current Applications of Gene Expression Profiling in the Clinical Management of Multiple Myeloma

Jean-Luc Harousseau, M.D., Hotel Dieu, Nantes, France
Stem Cell Transplantation in Multiple Myeloma

Paul Richardson, M.D., Dana-Farber Cancer Institute, Boston, MA
The Emerging Role of Novel Agents in the Treatment of Multiple Myeloma

Multiple Myeloma (MM) is a plasma cell neoplasm characterized by the accumulation of monoclonal plasma cells in the bone marrow, associated with the synthesis of a monoclonal immunoglobulin, and with a high incidence of osteolytic bone lesions. In the past few years, major advances have been made in understanding the molecular genetics and the cellular biology of myeloma cells, such as the new insights provided by gene expression profiling data. Although the disease is still regarded as incurable, two different approaches have led to a significant improvement in response and survival: stem cell transplantation and biologically based new therapies.

Dr. John Shaughnessy will present new data from gene expression profiling and will focus on the role of the Wnt-signaling antagonist, DKK1, in the development of osteolytic lesions in Multiple Myeloma. Overexpression of the DKK1 gene found in plasma cells from patients with bone lesions and the role of DKK1 on osteoblast differentiation will be discussed.

Dr. Jean-Luc Harousseau will discuss the role of double autologous transplantation in younger patients with Multiple Myeloma. He will also address the role of autologous transplantation followed by allogeneic stem cell transplantation with reduced intensity conditioning regimen (miniallotransplantation).

Dr. Paul Richardson will summarize recent developments of targeted therapy in Multiple Myeloma. He will present clinical results obtained with new agents, such as the proteasome-inhibitor (Bortezomid) and immunomodulatory drugs (Revlimid, Actimid). These agents have been evaluated in relapsed/refractory patients and are currently being tested in frontline therapy and in combination with dexamethasone or with cytotoxic agents.